case_id,count,combos,patient_info,document_name,Q4_baseline,Q4_rag,Q4_gt
Case8288,13,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top1_30retrieve_gpt_5_gpt_5_update', 'top1_30retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_30retrieve_gpt_5_gpt_5_update', 'top3_30retrieve_gpt_5_gpt_5_mini_update', 'top3_30retrieve_gpt_5_mini_gpt_5_update', 'top3_30retrieve_gpt_5_mini_gpt_5_mini_update']","Fetal imaging at 36 weeks' gestation is concerning for a major congenital cardiac anomaly and the pregnancy was referred by a developmental pediatrician for genetic evaluation. A chromosomal microarray (CMA) was previously performed and was nondiagnostic. There is a family history of an inborn error of metabolism affecting an older sibling, and the parents have had multiple sessions with a genetic counselor. Given the late-gestation identification of a significant cardiac malformation and the nondiagnostic CMA, whole exome sequencing (WES) is being pursued to evaluate for an underlying genetic etiology that could inform perinatal and postnatal management, with coverage through UHC noted.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case4512,9,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top1_30retrieve_gpt_5_gpt_5_update', 'top1_30retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_30retrieve_gpt_5_gpt_5_update', 'top3_30retrieve_gpt_5_gpt_5_mini_update']","The patient is a 21-year-old referred by the primary care physician for evaluation of a major congenital cardiac anomaly present since birth, and whole genome sequencing (WGS) is being pursued to identify a potential genetic etiology; there is a family history of a sibling who experienced a brief resolved unexplained event characterized by altered level of responsiveness with cyanosis, pallor, and irregular breathing which raised concern for a heritable predisposition, and no prior genetic testing has been performed, pre-test counseling was completed with a genetic counselor and a post-test visit is planned with testing submitted with coverage through BCBS_FEP.",BCBS_FEP_204102 Whole Exome and.pdf,No,Not Specified,No
Case3592,9,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top1_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top1_30retrieve_gpt_5_gpt_5_update', 'top1_30retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update', 'top3_30retrieve_gpt_5_gpt_5_update', 'top3_30retrieve_gpt_5_mini_gpt_5_update']","The patient is a neonate evaluated by a developmental pediatrician for unexplained epileptic encephalopathy with neonatal onset and no prior epilepsy multigene panel testing; chromosomal microarray (CMA) testing for developmental disorders is being requested. A prior chromosomal microarray was nondiagnostic. There is a family history of an older sibling with unexplained developmental regression unrelated to autism or epilepsy. Pre-test counseling was discussed with a genetic specialist and post-test follow-up is planned, and testing is being submitted with coverage through Cigna.",Cigna_MOL.TS_.150A_CMA_for_Developmental_Disorders_and_Prenatal_Diagnosis_eff01.01.2025_pub09.10.2024_1.pdf,No,Not Specified,No
Case5230,7,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_30retrieve_gpt_5_gpt_5_mini_update', 'top1_30retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_30retrieve_gpt_5_gpt_5_mini_update', 'top3_30retrieve_gpt_5_mini_gpt_5_mini_update']","The 15-year-old adolescent was referred by neurology for whole exome sequencing (WES) to evaluate a congenital anomaly after a nondiagnostic chromosomal microarray (CMA). There is a family history of an inborn error of metabolism in a sibling, the patient has coverage through UHC, and genetic counseling was declined at this time.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case5605,6,"['top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_30retrieve_gpt_5_gpt_5_update']","The patient is an 11-year-old being evaluated for a major congenital cardiac anomaly and was referred by an obstetrician for whole genome sequencing (WGS) to assess for an underlying genetic cause. A prior chromosomal microarray (CMA) was nondiagnostic, pre-test counseling was completed with a genetic specialist, and insurance coverage is through BCBS_FEP. Family history is notable for a maternal aunt with pancreatic cancer.",BCBS_FEP_204102 Whole Exome and.pdf,Yes,Not Specified,Yes
Case3422,6,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update']","The patient is a 34-year-old referred by oncology for evaluation of congenital choanal atresia and consideration of whole-exome sequencing (WES) to assess for an underlying genetic etiology after a nondiagnostic chromosomal microarray (CMA); the patient has Cigna coverage, has seen a genetic counselor multiple times, and reports a mother who was diagnosed with breast cancer at age 50.",Cigna_MOL.TS_.235.C_Whole_Exome_Sequencing_Cigna_eff01.01.2025_pub09.20.2024.pdf,Yes,Not Specified,Yes
Case14141,5,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update']","The patient is a 7-year-old referred by an oncologist for evaluation of multiple congenital anomalies and whole exome sequencing (WES) is planned to investigate an underlying genetic etiology, with prior chromosomal microarray (CMA) testing reported as nondiagnostic; there is a family history of global developmental delay in a sibling, coverage is through the Blue Cross Blue Shield Federal Employee Program (FEP), and pre-test genetic counseling has been completed with arrangements for post-test counseling and follow-up.",BCBS_FEP_204102 Whole Exome and.pdf,Yes,Not Specified,Yes
Case13406,5,"['top1_30retrieve_gpt_5_gpt_5_update', 'top1_30retrieve_gpt_5_gpt_5_mini_update', 'top1_30retrieve_gpt_5_mini_gpt_5_update', 'top3_30retrieve_gpt_5_gpt_5_update', 'top3_30retrieve_gpt_5_gpt_5_mini_update']","The infant is 6 weeks of age and is being evaluated for concern of global developmental delay, with a family history notable for a sibling who experienced a brief resolved unexplained event described as altered level of responsiveness with cyanosis, pallor, and irregular breathing; chromosomal microarray (CMA) was previously performed and was nondiagnostic. Whole genome sequencing (WGS) has been ordered by a medical geneticist to assess for an underlying genetic etiology, pre-test counseling has been completed, and the family will follow up with the genetic counselor after results, with testing submitted for coverage through UHC.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case10451,5,"['top1_10retrieve_gpt_5_gpt_5_update', 'top1_10retrieve_gpt_5_gpt_5_mini_update', 'top1_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update', 'top3_30retrieve_gpt_5_mini_gpt_5_mini_update']","The patient is a 10-year-old with moderate to severe intellectual disability diagnosed in childhood who was referred by neurology for whole exome sequencing (WES) to evaluate an unexplained neurodevelopmental disorder; prior chromosomal microarray (CMA) testing was nondiagnostic. There is a family history of a sibling who had a brief resolved unexplained event characterized by altered level of responsiveness with cyanosis, pallor, and irregular breathing. The neurologist placed the order, there is no documentation of prior genetic counseling, and testing will be pursued with coverage through UHC.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case14155,3,"['top1_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update']","The child is a 7-year-old referred by neurology for evaluation of autism spectrum disorder and whole genome sequencing (WGS) has been requested to assess for genetic contributors to the neurodevelopmental presentation. There is a family history notable for a maternal uncle with a persistent, severe immunologic disorder, which raised concern for an inherited predisposition that might overlap with neurodevelopmental features. There has been no prior genetic testing, and pre-test genetic counseling was declined by the family; testing is being pursued with coverage through Cigna.",Cigna_MOL.TS_.306.C_Whole_Genome_Sequencing_Cigna_eff01.01.2025_pub09.10.2024.pdf,No,Not Specified,No
Case5380,3,"['top1_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top1_30retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_update']","An 8-week-old infant is referred by neurology for evaluation of high-risk brief resolved unexplained events (BRUE) with recurrent witnessed seizure-like episodes, and whole genome sequencing (WGS) is requested to assess for an underlying genetic cause; prior chromosomal microarray (CMA) testing was nondiagnostic, and there is a maternal history of short stature as a growth abnormality, the family declined pre-test genetic counseling, and testing will be pursued with coverage through UHC.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,Not Specified,Yes
Case3677,2,"['top1_30retrieve_gpt_5_gpt_5_update', 'top3_30retrieve_gpt_5_mini_gpt_5_update']","She is a 46-year-old woman with a personal history of breast cancer who is undergoing BRCA1/2 testing because of a close relative with pancreatic cancer and multiple other primary solid tumors on the same side of the family; prior chromosomal microarray (CMA) testing was nondiagnostic. The patient was referred by a nurse practitioner and completed pre-test genetic counseling with plans for post-test follow-up, and testing will be billed to UHC. Her family history is notable for a mother with pancreatic cancer and at least two additional affected relatives on the maternal side.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Not Specified,Yes,Not Specified
Case19321,2,"['top1_10retrieve_gpt_5_gpt_5_mini_update', 'top3_30retrieve_gpt_5_gpt_5_mini_update']","The patient is a 1-year-old referred by a neurologist for evaluation of a complex neurodevelopmental disorder with features concerning for autism spectrum disorder, and whole exome sequencing (WES) is being pursued to investigate a possible genetic etiology; prior chromosomal microarray (CMA) testing was nondiagnostic. A maternal aunt is reported to have multiple congenital anomalies, pre-test genetic counseling was completed, and plans are in place for post-test follow-up, with coverage through UHC.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,Not Specified,Yes
Case11855,2,"['top1_30retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update']","The patient is a 14-year-old being evaluated by a developmental pediatrician for a congenital anomaly affecting a single organ system with concern for an underlying genetic etiology, and chromosomal microarray (CMA) is being ordered to assess for copy number variants associated with developmental disorders; Fragile X testing was previously performed and was nondiagnostic. There is a family history notable for a maternal aunt with triple-negative breast cancer, which was discussed as part of the risk assessment during pre-test counseling. Pre-test counseling was completed with a genetic specialist and plans for post-test follow-up were made, and testing will be pursued with coverage through UHC.",United Healthcare_chromosome-microarray-testing.pdf,Not Specified,Yes,Not Specified
Case11514,2,"['top1_30retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update']","The 10-year-old patient is being evaluated for conjugated hyperbilirubinemia not attributable to total parenteral nutrition and whole exome sequencing (WES) has been requested to investigate a potential genetic cause of cholestatic liver disease; a chromosomal microarray (CMA) was previously performed and was nondiagnostic. There is a family history of an inborn error of metabolism in a cousin, which raises concern for an inherited metabolic disorder contributing to the hepatic phenotype. The test was ordered by the patient's oncologist, coverage is through UHC, and there is no documentation of pre-test genetic counseling.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case14408,2,"['top3_10retrieve_gpt_5_mini_gpt_5_update', 'top3_10retrieve_gpt_5_mini_gpt_5_mini_update']","The patient is a 75-year-old who was referred by a family medicine physician for BRCA1/2 testing because of dysmorphic features and a family history notable for a brother with breast cancer; there is no prior genetic testing, pre-test counseling was completed and post-test follow-up with a genetic counselor is planned, and testing will be billed through Cigna.",Cigna_MOL.TS_.238.A_BRCA_Analysis_eff01.01.2025_pub09.10.2024_1.pdf,Not Specified,Yes,Not Specified
Case18257,2,"['top1_30retrieve_gpt_5_gpt_5_mini_update', 'top3_10retrieve_gpt_5_gpt_5_mini_update']","The 64-year-old patient has a history of breast cancer diagnosed at age 50 or younger and is being evaluated for BRCA1/2 testing to assess hereditary breast and ovarian cancer risk. Chromosomal microarray (CMA) testing was previously performed and was nondiagnostic, family history is notable for a sibling with short stature, the test was ordered by the patient's general practitioner, there is no documentation of prior genetic counseling, and coverage is through Cigna.",Cigna_MOL.TS_.238.A_BRCA_Analysis_eff01.01.2025_pub09.10.2024_1.pdf,Not Specified,No,Not Specified
Case17822,2,"['top1_10retrieve_gpt_5_mini_gpt_5_mini_update', 'top3_30retrieve_gpt_5_mini_gpt_5_mini_update']","The patient is a 13-year-old referred to medical genetics for evaluation of multiple congenital anomalies affecting different organ systems, and whole genome sequencing (WGS) has been ordered as the next-tier diagnostic test after a nondiagnostic chromosomal microarray (CMA). The family history is notable for a sibling with short stature, genetic counseling was declined prior to testing, and the order was placed by a medical geneticist with coverage through UHC, with plans to review results and coordinate further evaluation and management as indicated.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case16246,1,['top1_10retrieve_gpt_5_mini_gpt_5_mini_update'],"The patient is a 35-year-old woman with a personal history of breast cancer who meets criteria for hereditary testing because her diagnosis occurred before age 50, and she is being referred by her gynecologist for BRCA1 and BRCA2 testing with coverage through UHC; she reports a family history notable for an uncle with pancreatic cancer, prior karyotype testing was performed and was nondiagnostic, and no pre-test genetic counseling has been conducted.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Not Specified,No,Not Specified
Case12834,1,['top3_10retrieve_gpt_5_gpt_5_update'],"The patient is a 16-year-old referred by a developmental pediatrician for evaluation of a complex neurodevelopmental disorder affecting at least one organ system, and chromosomal microarray (CMA) testing has been ordered although the requisition specifies a tumor-type rather than a germline assay; prior Fragile X testing was nondiagnostic. There is a family history notable for a maternal uncle with a movement disorder described as dystonia and ataxia, genetic counseling is not documented in the record, and testing will be billed through Cigna.",Cigna_MOL.TS_.344.A_Chromosomal_Microarray_Solid_Tumors_eff01.01.2025_pub09.11.2024_0.pdf,Not Specified,No,Not Specified
Case10363,1,['top1_10retrieve_gpt_5_mini_gpt_5_mini_update'],The patient is a 7-year-old child with a congenital anomaly present since birth who was referred by the general practitioner for whole genome sequencing (WGS) after fluorescence in situ hybridization (FISH) testing was nondiagnostic. The family history is notable for a maternal aunt with pancreatic cancer and the family has coverage through UHC. The patient has been seen multiple times by a genetic counselor for pre-test counseling and plans for post-test follow-up are in place. WGS is being pursued to provide a comprehensive genomic evaluation given the longstanding congenital findings and prior nondiagnostic targeted testing.,United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,Not Specified,Yes
Case19255,1,['top1_10retrieve_gpt_5_gpt_5_mini_update'],"The patient is a 38-year-old woman with a history of two separate primary breast cancers who was referred by her neurologist for BRCA1/2 testing to evaluate for hereditary breast and ovarian cancer predisposition, she reports a family history notable for a father with metastatic prostate cancer, prior fluorescence in situ hybridization testing was nondiagnostic, and pre-test counseling was completed with a genetic specialist with testing to be pursued with coverage through UHC.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Not Specified,Yes,Not Specified
Case5674,1,['top1_30retrieve_gpt_5_mini_gpt_5_mini_update'],"A 9-year-old child with persistent seizures is being evaluated by a general practitioner and has had multiple visits with a genetic counselor; a prior chromosomal microarray (CMA) was nondiagnostic, and the team plans whole exome sequencing (WES) to investigate a possible genetic epilepsy syndrome given a family history notable for sudden unexplained death in an uncle before age 35, with testing requested under BCBS_FEP and arrangements for post-test follow-up with genetics.",BCBS_FEP_204102 Whole Exome and.pdf,Yes,Not Specified,Yes
Case6478,1,['top3_30retrieve_gpt_5_mini_gpt_5_update'],"A 52-year-old man with metastatic prostate cancer is being referred by his general practitioner for germline BRCA1 and BRCA2 testing because of a family history notable for a father with pancreatic cancer; he has had no prior genetic testing, pre-test genetic counseling was not completed, and testing is being pursued with coverage through UHC to inform therapeutic options and cascade testing for at-risk relatives with plans for post-test counseling and oncology follow-up once results are available.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Not Specified,No,Not Specified
Case7376,1,['top1_10retrieve_gpt_5_mini_gpt_5_mini_update'],"The patient is a 73-year-old referred by a neurologist for evaluation of a major abnormality involving at least one organ system that remains unexplained, and whole exome sequencing (WES) has been ordered for diagnostic clarification. Prior fluorescent in situ hybridization testing was nondiagnostic. The patient reports that a sister had triple negative breast cancer, which raises concern for an underlying heritable predisposition. Pre-test counseling was completed with a genetic specialist and testing will proceed with coverage through UHC.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,No,Yes
Case8621,1,['top1_10retrieve_gpt_5_gpt_5_mini_update'],"A 2-year-old child with a complex neurodevelopmental disorder with autism is undergoing evaluation with whole exome sequencing (WES) to seek a unifying diagnosis after prior chromosomal microarray (CMA) testing was nondiagnostic; the test was ordered by the childâ€™s oncologist and is planned with coverage through UHC, the family reports an uncle with a congenital anomaly as relevant family history, and the family has met with a genetic counselor multiple times with pre-test counseling completed and plans for post-test follow-up.",United Healthcare_whole-exome-and-whole-genome-sequencing.pdf,Yes,Not Specified,Yes
